Nasdaq

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

Shares of SAB Biotherapeutics SABS plunged almost 40% on Wednesday after SABS announced discontinuing enrollment in the phase III ACTIV-2 study, which is evaluating its investigational antibody ...
Nasdaq

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

Positive clinical results confirm that SAB’s fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variants—a valuable feature when addressing rapidly mutating ...
Yahoo Finance

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN

Sab Biotherapeutics’ New Study Targets Type 1 Diabetes Progression

Sab Biotherapeutics, Inc. ((SABS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...